TITLE

An Anti-Urokinase Plasminogen Activator Receptor Antibody (ATN-658) Blocks Prostate Cancer Invasion, Migration, Growth, and Experimental Skeletal Metastasis In Vitro and In Vivo

AUTHOR(S)
Rabbani, Shafaat A.; Ateeq, Bushra; Arakelian, Ani; Valentino, Maria Luisa; Shaw, David E.; Dauffenbach, Lisa M.; Kerfoot, Christopher A.; Mazar, Andrew P.
PUB. DATE
October 2010
SOURCE
Neoplasia;Oct2010, Vol. 12 Issue 10, p778
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Urokinase plasminogen activator receptor (uPAR) is a multidomain protein that plays important roles in the growth, invasion, and metastasis of a number of cancers. In the present study, we examined the effects of administration of a monoclonal anti-uPAR antibody (ATN-658) on prostate cancer progression in vitro and in vivo. We examined the effect of treatment of ATN-658 on human prostate cancer cell invasion, migration, proliferation, and regulation of intracellular signaling pathways. For in vivo studies, PC-3 cells (1 x 106) were inoculated into the right flank of male Balb C nu/nu mice through subcutaneous or through intratibial route (2 x 105) of male Fox Chase severe combined immunodeficient mice to monitor the effect on tumor growth and skeletal metastasis. Treatment with ATN-658 resulted in a significant dose-dependent decrease in PC-3 cell invasion and migration without affecting cell doubling time. Western blot analysis showed that ATN-658 treatment decreased the phosphorylation of serine/threonine protein kinase B (AKT), mitogen-activated protein kinase (MAPK), and focal adhesion kinase (FAK) without affecting AKT, MAPK, and FAK total protein expression. In in vivo studies, ATN-658 caused a significant decrease in tumor volume and a marked reduction in skeletal lesions as determined by Faxitron x-ray and micro-computed tomography. Immunohistochemical analysis of subcutaneous and tibial tumors showed a marked decrease in the levels of expression of pAKT, pMAPK, and pFAK, consistent with the in vitro observations. Results from these studies provide compelling evidence for the continued development of ATN-658 as a potential therapeutic agent for the treatment of prostate and other cancers expressing uPAR.
ACCESSION #
56947790

Tags: UROKINASE;  CANCER invasiveness;  METASTASIS;  PROSTATE -- Cancer;  CELL adhesion

 

Related Articles

  • CXCR4 Chemokine Receptor Mediates Prostate Tumor Cell Adhesion through a5 and �3 Integrins. Engl, Tobias; Relja, Borna; Marian, Dana; Blumenberg, Christa; M�ller, Iris; Beecken, Wolf-Dietrich; Jones, Jon; Ringel, Eva M.; Bereiter-Hahn, J�rgen; Jonas, Dietger; Blaheta, Roman A. // Neoplasia;Apr2006, Vol. 8 Issue 4, p290 

    The mechanisms leading to prostate cancer metastasis are not understood completely. Although there is evidence that the CXC chemokine receptor (CXCR) 4 and its ligand CXCL12 may regulate tumor dissemination, their role in prostate cancer is controversial. We examined CXCR4 expression and...

  • Neurologic Complications of Prostate Cancer. Benjamin, Ramsis // American Family Physician;5/1/2002, Vol. 65 Issue 9, p1834 

    Provides information on neurologic complications of prostate cancer. Details on the anatomy of the disease; Symptoms and diagnosis of spinal metastasis; Treatment of brain metastasis.

  • Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Adams, Jason Y.; Johnson, Mai; Sato, Makoto; Berger, Frank; Gambhir, Sanjiv S.; Carey, Michael; Iruela-Arispe, M. Luisa; Wu, Lily // Nature Medicine;Aug2002, Vol. 8 Issue 8, p891 

    Non-invasive imaging and transcriptional targeting can improve the safety of therapeutic approaches in cancer. Here we demonstrate the ability to identify metastases in a human-prostate cancer model, employing a prostate-specific adenovirus vector (AdPSE-BC-luc) and a charge-coupled...

  • Poorer prostate cancer outcome linked with Cox-2 overexpression.  // Hem/Onc Today;1/1/2008, Vol. 9 Issue 1, p14 

    The article discusses research being done on the association between over expression and radiotherapy and higher rates of failure and metastasis. It references a study by researchers in the Translational Research Program at the Radiation Therapy Oncology Group in Philadelphia, Pennsylvania,...

  • Single cell adhesion measuring apparatus (SCAMA): application to cancer cell lines of different metastatic potential and voltage-gated Na+ channel expression. Palmer, Christopher P.; Mycielska, Maria E.; Burcu, Hakan; Osman, Kareem; Collins, Timothy; Beckerman, Rachel; Perrett, Rebecca; Johnson, Helen; Aydar, Ebru; Djamgoz, Mustafa B. A. // European Biophysics Journal;Apr2008, Vol. 37 Issue 4, p359 

    We have developed a simple yet effective apparatus, based upon negative pressure directed to the tip of a micro-pipette, to measure the adhesiveness of single cells. The �single cell adhesion measuring apparatus� (SCAMA) could differentiate between the adhesion of strongly versus...

  • Circulating Levels of VCAM and MMP-2 May Help Identify Patients with More Aggressive Prostate Cancer. De Cicco, Concetta; Ravasi, Laura; Zorzino, Laura; Sandri, Maria Teresa; Botteri, Edoardo; Verweij, Fabrizio; Granchi, Donatella; De Cobelli, Ottavio; Paganelli, Giovanni // Current Cancer Drug Targets;May2008, Vol. 8 Issue 3, p199 

    Background: Prostate adenocarcinoma is generally characterized by slow progression although some phenotypes have a more aggressive behavior with tendency to local invasion and distant metastases, mainly to bones. Better specific care could be provided to the aggressive phenotype-group of...

  • DLC1 induces expression of E-cadherin in prostate cancer cells through Rho pathway and suppresses invasion. Tripathi, V; Popescu, N C; Zimonjic, D B // Oncogene;2/6/2014, Vol. 33 Issue 6, p724 

    E-cadherin is a cell-cell adhesion molecule that acts as a suppressor of cancer cell invasion and its expression is downregulated in many advanced, poorly differentiated, human cancers. In this study, we found that the expression of DLC1 (deleted in liver cancer 1) tumor-suppressor gene in...

  • PDGF Upregulates Mcl-1 Through Activation of b-Catenin and HIF-1α-Dependent Signaling in Human Prostate Cancer Cells. Iqbal, Shareen; Shumin Zhang; Driss, Adel; Zhi-Ren Liu; Hyeong-Reh Choi Kim; Yanru Wang; Ritenour, Chad; Zhau, Haiyen E.; Kucuk, Omer; Chung, Leland W. K.; Daqing Wu // PLoS ONE;Jan2012, Vol. 7 Issue 1, p1 

    Background: Aberrant platelet derived growth factor (PDGF) signaling has been associated with prostate cancer (PCa) progression. However, its role in the regulation of PCa cell growth and survival has not been well characterized. Methodology/Principal Findings: Using experimental models that...

  • Selection of cell lines with enhanced invasive phenotype from xenografts of the human prostate cancer cell line WPE1-NB26. Rivette, Amanda S.; Tokar, Erik J.; Williams, Daniel E.; Mackenzie, Charles D.; Ablin, Richard J.; Webber, Mukta M. // Journal of Experimental Therapeutics & Oncology;2005, Vol. 5 Issue 2, p111 

    Prostate cancer is a leading cause of death from cancer in American men and metastasis the main cause of death. To better understand the disease and accelerate development of new therapies, in vivo models that reflect different disease stages are needed. A family of cell lines that...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics